ENVB Should I Buy

ENVB is not a good buy right now for a beginner long-term investor with $50k–$100k. The stock just dropped sharply (regular session -21.31% after a -18.88% pre-market move) and the latest news is a small capital raise with warrants—typically a dilution overhang for micro-cap biotechs. With no revenue, ongoing losses, no bullish proprietary signals today, and weak near-term statistical trend odds, the risk/reward is unfavorable for new money at this moment.

Price/Trend: ENVB saw a major downside break today (large single-day decline), signaling bearish momentum despite a small post-market bounce (+1.43%). Momentum: RSI(6) ~29.5 (oversold/near-oversold), which can allow short bounces, but does not confirm a trend reversal. MACD: Histogram is slightly positive (0.0696) but “positively contracting,” which suggests weakening upside momentum rather than strengthening. Moving Averages: Converging MAs indicate indecision; given today’s sharp drop, the immediate trend bias remains down. Levels: Pivot 4.054 is above the post-market price (3.54), implying price is below a key pivot. Support is near S1 3.569 (price is essentially at/just below this area) with next support S2 3.27. Resistance levels are R1 4.54 and R2 4.839. Pattern-based short-term odds (provided): ~50% chance of -0.34% next day, -6.77% next week, -0.81% next month—skewing negative near-term.